178 related articles for article (PubMed ID: 1373997)
1. Reduction of graft-versus-host reactivity after small bowel transplantation: ex vivo treatment of intestinal allografts with an anti-T cell immunotoxin.
Clark CL; Smith GJ; Crane PW; Price BA; Lear PA; Fabre JW; Wood RF
Clin Exp Immunol; 1992 May; 88(2):220-5. PubMed ID: 1373997
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo perfusion of intestinal allografts with anti-T cell monoclonal antibody/ricin A chain conjugates for the suppression of graft-versus-host disease.
Smith GJ; Ingham-Clark C; Crane P; Lear P; Wood RF; Fabre JW
Transplantation; 1992 Apr; 53(4):717-22. PubMed ID: 1566334
[TBL] [Abstract][Full Text] [Related]
3. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
[TBL] [Abstract][Full Text] [Related]
4. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
5. Graft versus host disease in small bowel transplantation.
Clark CL; Price BA; Malcolm P; Lear PA; Wood RF
Br J Surg; 1991 Sep; 78(9):1077-9. PubMed ID: 1933190
[TBL] [Abstract][Full Text] [Related]
6. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
[No Abstract] [Full Text] [Related]
7. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
Byers VS; Henslee PJ; Kernan NA; Blazar BR; Gingrich R; Phillips GL; LeMaistre CF; Gilliland G; Antin JH; Martin P
Blood; 1990 Apr; 75(7):1426-32. PubMed ID: 2180494
[TBL] [Abstract][Full Text] [Related]
8. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
9. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
[TBL] [Abstract][Full Text] [Related]
10. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
[TBL] [Abstract][Full Text] [Related]
12. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.
Martin PJ; Hansen JA; Torok-Storb B; Moretti L; Press O; Storb R; Thomas ED; Weiden PL; Vitetta ES
Bone Marrow Transplant; 1988 Sep; 3(5):437-44. PubMed ID: 2973360
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
Martin PJ; Pei J; Gooley T; Anasetti C; Appelbaum FR; Deeg J; Hansen JA; Nash RA; Petersdorf EW; Storb R; Ghetie V; Schindler J; Vitetta ES
Biol Blood Marrow Transplant; 2004 Aug; 10(8):552-60. PubMed ID: 15282533
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host reaction in small-bowel transplantation and possibilities for its circumvention.
Watanabe K; Yagi T; Iwagaki H; Kimura Y; Mitsuoka N; Inagaki M; Tanaka S; Tanaka N
J Int Med Res; 2001; 29(3):222-8. PubMed ID: 11471860
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
Martin PJ; Nelson BJ; Appelbaum FR; Anasetti C; Deeg HJ; Hansen JA; McDonald GB; Nash RA; Sullivan KM; Witherspoon RP; Scannon PJ; Friedmann N; Storb R
Blood; 1996 Aug; 88(3):824-30. PubMed ID: 8704237
[TBL] [Abstract][Full Text] [Related]
18. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
[TBL] [Abstract][Full Text] [Related]
19. The role of natural killer cell mediated caspases activation in a graft-versus-host disease model of semiallogeneic small bowel transplantation.
Fändrich F; Zepernick-Kalinski C; Gebhardt H; Henne-Bruns D; Zavazava N; Lin X
Transpl Immunol; 1999 Mar; 7(1):1-7. PubMed ID: 10375071
[TBL] [Abstract][Full Text] [Related]
20. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant.
Henslee-Downey PJ; Parrish RS; MacDonald JS; Romond EH; Marciniak E; Coffey C; Ciocci G; Thompson JS
Transplantation; 1996 Mar; 61(5):738-45. PubMed ID: 8607177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
